In the treatment of pancreatic ductal adenocarcinoma (PDAC), although targets such as KRAS and BRCA mutations have received considerable attention, their clinical application is often constrained by mutation frequencies or limitations to specific patient subgroups (Wei and Ren, 2024; Sarantis et al., 2020). The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.